Tuesday, August 5, 2014

TesoRx Gets $10M

Menlo Park-based TesoRx, which is developing specialty pharmaceuticals currently focused on oral delivery of testosterone, has raised $10M in a Series B-1 funding. The company said the funding came from existing and new private investors. Names of those investors was not announced. The company, led by Ramachandran "TR" Thirucote, Ph.D., said the funds go towards its Phase 3 trials, to advance its pipeline, and for commercial manufacturing facilities. More information »